Permethrin - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for permethrin and what is the scope of freedom to operate?
Permethrin
is the generic ingredient in three branded drugs marketed by Aurobindo Pharma Usa, Actavis Labs, Dr Reddys Labs Eu, Encube Ethicals, Padagis Israel, Glaxosmithkline, Medtech Products, Actavis Mid Atlantic, and Perrigo New York, and is included in nine NDAs. Additional information is available in the individual branded drug profile pages.There are five drug master file entries for permethrin. Fourteen suppliers are listed for this compound.
Summary for permethrin
| US Patents: | 0 |
| Tradenames: | 3 |
| Applicants: | 9 |
| NDAs: | 9 |
| Drug Master File Entries: | 5 |
| Finished Product Suppliers / Packagers: | 14 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Clinical Trials: | 37 |
| Drug Prices: | Drug price trends for permethrin |
| Drug Sales Revenues: | Drug sales revenues for permethrin |
| What excipients (inactive ingredients) are in permethrin? | permethrin excipients list |
| DailyMed Link: | permethrin at DailyMed |
Recent Clinical Trials for permethrin
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| College of Physicians and Surgeons Pakistan | EARLY_PHASE1 |
| Children Hospital and Institute of Child Health, Lahore | PHASE2 |
| Infectopharm Arzneimittel GmbH | PHASE3 |
Pharmacology for permethrin
| Drug Class | Pyrethroid |
Medical Subject Heading (MeSH) Categories for permethrin
Anatomical Therapeutic Chemical (ATC) Classes for permethrin
US Patents and Regulatory Information for permethrin
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Actavis Mid Atlantic | PERMETHRIN | permethrin | LOTION;TOPICAL | 075014-001 | Mar 28, 2000 | OTC | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Aurobindo Pharma Usa | ELIMITE | permethrin | CREAM;TOPICAL | 019855-001 | Aug 25, 1989 | AB | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Perrigo New York | PERMETHRIN | permethrin | LOTION;TOPICAL | 076090-001 | Dec 20, 2001 | OTC | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Encube Ethicals | PERMETHRIN | permethrin | CREAM;TOPICAL | 211303-001 | Apr 3, 2019 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for permethrin
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Glaxosmithkline | NIX | permethrin | LOTION;TOPICAL | 019435-001 | Mar 31, 1986 | ⤷ Start Trial | ⤷ Start Trial |
| Medtech Products | NIX | permethrin | LOTION;TOPICAL | 019918-001 | May 2, 1990 | ⤷ Start Trial | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Market Dynamics and Financial Trajectory for Permethrin
More… ↓
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.


